Temozolomide (Amitzo) for grade III or IV brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial studies a new form of the chemotherapy drug temozolomide (called Amitzo) in people with aggressive brain tumors (grade III or IV gliomas). It aims to see if the drug is safe and effective, and is for patients who need treatment for a new diagnosis or for tumors that have come back after standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a grade III or IV glioma (a type of brain tumor), either newly diagnosed or returned after standard treatment.
- You must be between 18 and 80 years old.
- You must have had an MRI scan before starting the study.
- You must be willing and able to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares standard radiation therapy versus radiation plus a chemotherapy medicine called temozolomide in people with a newly diagnosed low-grade (WHO grade II) brain glioma after surgery. It’s designed to see if adding temozolomide improves outcomes while managing side effects.
This trial tests a daily chemo drug (temozolomide) in patients aged 65 or older with a specific type of aggressive brain cancer that has a certain genetic marker. It aims to see if this daily schedule works well after initial radiation and chemo.
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
This trial tests giving a chemotherapy drug called temozolomide before radiation therapy to people with a newly diagnosed high-grade brain tumor. The goal is to see if this approach can help control the tumor better.
This trial tests a combination of two drugs (temozolomide and dexbrompheniramine) to treat high-grade gliomas that have come back after standard treatment. The goal is to see if this combination can help control the tumor or slow its growth.
This trial tests a new combination of two drugs (tarlatamab and temozolomide) for people with certain types of aggressive brain or central nervous system tumors that have come back or not responded to standard treatment. The hope is that this combination may work better against tumors that have a specific marker called DLL3.
Hear when a new Brain Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.